David Horst
Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
Jurmeister P, Büttner R, Merkelbach-Bruse S, Kreipe H, Jonigk D, Jochum W, Rodriguez R, Dietel M, Horst D, Hummel M, Kirchner T, Neumann J, Vollbrecht C, Jöhrens K, Aust D, Behnke A, Stenzinger A, Penzel R, Endris V, Schirmacher P, Fisseler-Eckhoff A, von Laffert M. Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing. Virchows Arch 2021; 479:247-255.
Jun 25, 2021Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
Jun 25, 2021Virchows Arch 2021; 479:247-255
Jurmeister Philipp, Büttner Reinhard, Merkelbach-Bruse Sabine, Kreipe Hans, Jonigk Danny, Jochum Wolfram, Rodriguez Regulo, Dietel Manfred, Horst David, Hummel Michael, Kirchner Thomas, Neumann Jens, Vollbrecht Claudia, Jöhrens Korinna, Aust Daniela, Behnke Anke, Stenzinger Albrecht, Penzel Roland, Endris Volker, Schirmacher Peter, Fisseler-Eckhoff Annette, von Laffert Maximilian
p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors
Wassermann S, Kirchner T, Brabletz T, Merkel S, Reu S, Kriegl L, Haynl A, Hlubek F, Horst D, Palmqvist R, Hiendlmeyer E, Scheel S, Jung A. p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors. Gastroenterology 2009; 136:196-205.e2.
Jan 1, 2009p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors
Jan 1, 2009Gastroenterology 2009; 136:196-205.e2
Wassermann Stella, Kirchner Thomas, Brabletz Thomas, Merkel Susanne, Reu Simone, Kriegl Lydia, Haynl Angela, Hlubek Falk, Horst David, Palmqvist Richard, Hiendlmeyer Elke, Scheel Silvio K, Jung Andreas